" class="no-js "lang="en-US"> Dwaine Vance, Randox, on Molecular Diagnostics
Tuesday, May 27, 2025

Dwaine Vance, Randox, on Molecular Diagnostics

At ECCMID, we caught up with Dwaine Vance from Randox, who discusses his company’s contribution to the field of diagnostics and healthcare. Randox is a leading provider of innovative diagnostic solutions for various medical applications.

Vance begins by highlighting Randox’s commitment to improving patient outcomes through advanced diagnostic technologies. He mentions the company’s extensive range of diagnostic products, including tests for infectious diseases.

He goes on to discuss Randox’s dedication to research and development, emphasizing the company’s investment in cutting-edge technologies and collaborations with renowned institutions. Vance explains that Randox’s focus is on developing accurate and reliable diagnostic tests that can aid in early disease detection, personalized treatment, and improved patient care.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more